埃索美拉唑（Nexium）上市了吗？

Is esomeprazole (Nexium) on the market? Esomeprazole (Nexium) has been launched in many places. It was first launched in Sweden in 2000 and will be launched in China in 2020.

In 2000, the oral formulation of esomeprazole (Nexium) was first launched in Sweden. In 2001, it was approved by the FDA to be launched in the United States under the trade name Nexium. In 2003, esomeprazole sodium for injection developed by AstraZeneca was first launched in Sweden and was approved for marketing in the United States in 2005. On July 30, 2020, AstraZeneca announced that the China National Medical Products Administration (NMPA) officially approved esomeprazole (Nexium) injection for the prevention of stress ulcer bleeding in severe patients.

The mechanism of action of esomeprazole (Nexium) is the same as that of omeprazole. That is, when protonated under acidic conditions, esomeprazole is converted into sulfenamide, a compound that inhibits H+/K+-ATPase activity. It quickly combines with the sulfhydryl group of cysteine on the H+/K+-ATPase to form a disulfide bond, thereby inactivating the enzyme. It specifically inhibits H+/K+-ATPase activity in gastric parietal cells and thereby inhibits gastric acid secretion. Existing studies on acid-suppressing ability show that intravenous esomeprazole has the same acid-suppressing effect as oral esomeprazole when administered repeatedly.

Patients should pay attention to the following conditions when using esomeprazole: When any alarm symptoms occur (such as significant involuntary weight loss, repeated vomiting, dysphagia, hematemesis or melena), when gastric ulcer is suspected or gastric ulcer is already present, malignant tumors should be excluded, because treatment with esomeprazole magnesium enteric-coated tablets can reduce symptoms and delay diagnosis. Patients treated with this drug for a long period of time (especially those treated for more than 1 year) should be monitored regularly. Patients receiving on-demand treatment should be advised to contact their physician if the characteristics of their symptoms change.